Acadia Pharmaceuticals Files 8-K on Shareholder Votes

Ticker: ACAD · Form: 8-K · Filed: 2025-05-29T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: ACAD

TL;DR

Acadia Pharma held a shareholder vote, details to follow.

AI Summary

Acadia Pharmaceuticals Inc. filed an 8-K on May 29, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the proposals or the outcome of any votes.

Why It Matters

This filing indicates that Acadia Pharmaceuticals Inc. has held or is holding a vote of its shareholders, which is a standard corporate governance event.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not involve significant financial or operational changes.

Key Players & Entities

ACADIA PHARMACEUTICALS INC (company) — Registrant
May 29, 2025 (date) — Date of Report
Delaware (jurisdiction) — State of Incorporation
000-50768 (filing_id) — SEC File Number
06-1376651 (ein) — IRS Employer Identification No.
12830 El Camino Real, Suite 400 (address) — Principal Executive Offices
San Diego, California (location) — Principal Executive Offices City and State
92130 (zip_code) — Principal Executive Offices Zip Code
(858) 558-2871 (phone_number) — Registrant's Telephone Number

FAQ

What specific matters were submitted to a vote of Acadia Pharmaceuticals Inc.'s security holders?

The filing states that it is a report on "Submission of Matters to a Vote of Security Holders" but does not detail the specific proposals voted upon.

When was the report filed with the SEC?

The report was filed on May 29, 2025.

What is the company's principal executive office address?

The principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130.

What is the company's telephone number?

The company's telephone number, including area code, is (858) 558-2871.

In which state was Acadia Pharmaceuticals Inc. incorporated?

Acadia Pharmaceuticals Inc. was incorporated in Delaware.

From the Filing

0001193125-25-130620.txt : 20250529 0001193125-25-130620.hdr.sgml : 20250529 20250529160635 ACCESSION NUMBER: 0001193125-25-130620 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250529 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250529 DATE AS OF CHANGE: 20250529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 251003331 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 d16794d8k.htm 8-K 8-K ACADIA PHARMACEUTICALS INC false 0001070494 0001070494 2025-05-29 2025-05-29     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025     Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   000-50768   06-1376651 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12830 El Camino Real , Suite 400   San Diego , California   92130 (Address of Principal Executive Offices)   (Zip Code) Registrant’s Telephone Number, Including Area Code: (858) 558-2871 N/A (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.07 Submission of Matters to a Vote of Security Holders. (a) On May 29, 2025, Acadia Pharmaceuticals Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).   (b) The election of three nominees to serve as Class III directors on the Company’s Board of Directors until the Company’s 2028 Annual Meeting of Stockholders was carried out at the 2025 Annual Meeting. The following three Class III directors were elected by the votes indicated:        For      Withheld      Broker N